PolarityTE Inc.

PolarityTE — Investor Presentation (May 2022)

37 slides from PolarityTE's investor presentation, May 19, 2022

  1. Slide 1: Investor Presentation

    Investor Presentation Polarity TE manic Where Self Regenerates Self” M ay 2022

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement @ rosie This presentation contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties and investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Forward-look

  3. Slide 3: PolarityTE History

    PolarityTE History @ rosie * Founded in 2016 by MD/PhD from John Hopkins * Autologous cell & tissue technology platform for skin regeneration ¢ SkinTE® was previously marketed as 361 HCT/P—1,200 patients treated * Pivoted to 351/BLA pathway—off market as 361 HCT/P in May 2021 after end of enforcemen

  4. Slide 4: Leveraging Pre-BLA Commercial Experience

    Leveraging Pre-BLA Commercial Experience @ roeviye: Where Self Regenerates Sef” Experiential Refined Indication Developed Real World Learnings Positioning Evidence Optimized product Full-thickness DFUs with Informed trial design facturi manuractanng eup ceed stnieeites Evidence was leveraged during

  5. Slide 5: SkinTE: De-Risked Asset Leading to Significant Market Opportunity

    SkinTE®: De-Risked Asset Leading to 2 Significant Market Opportunity Phase 3 IND Approved Jan 2022 for Chronic Cutaneous Ulcer Indication g First pivotal trial—COVER DFUs—commenced enrollment in early Q2 2022 g RMAT Designation Granted May 2022 Scientific Body of Evidence g DFU and VLU RCTs totaling

  6. Slide 6: BLA Value Proposition

    BLA Value Proposition @ rosie = FDA/BLA approval requires robust data to establish safety and efficacy = Potential to drive broad adoption and enhance reimbursement post-approval * SkinTE pricing expected to be based on cost-effectiveness = Expanded market opportunities » Additional or supplemental

  7. Slide 7: Chronic Wounds: A Large and Growing Health and Economic Problem

    Chronic Wounds: A Large and Growing @ Health and Economic Problem 6.5m More than $25 Billion Affected Patients in the US per year spent on chronic wound care annually in the US With an expected increase in lifetime incidence of Diabetes and an aging US Population CCUs are expected to rise y drastica

  8. Slide 8: SkinTE — A Different Approach to Solving the Problem

    PolarityTE" Where Self Regenerates Sef” SkinTE — A Different Approach to Solving > the Problem Unique clinical attributes of SkinTE have the potential to create a new approach for hard-to-heal chronic and acute wounds Current Treatments Options SkinTE ter Limitations Autologous, multi-cellular treat

  9. Slide 9: Science of SkinTE

    @ SkiniE autologous heterogenous skin construct Science of SkinTE © 2022 PolarityTE, Inc., All Rights Reserved. Confidential

  10. Slide 10: Biology of Skin

    Biology of Skin @ roeviye: Where Self Regenerates Sef” © 2022 PolarityTE, Inc. All Rights Reserved. For Investors Only. Not For General Distribution.

  11. Slide 11: Healing is Not Homeostasis

    Healing is Not Homeostasis >) PolarityTE Where Self Regenerates Seff Hemostasis Inflammation Thermally- damaged. ‘Collagen a el 2008 Nature Gurtner et al. % 2018 Quant Imag Med Surg Deegan et al. © 2022 PolarityTE, Inc. All Rights Reserved. For Investors Only. Not For General Distribution. 11

  12. Slide 12: Healing is Not Homeostasis

    Healing is Not Homeostasis @ roeviye: Epidermis Epidermal Cells Sebaceous ) Follicular Gland Cells > Bulge Cells Interfollicular Dermis Cells Adipose Derived Cells one. ior 8 est Benjamin Raja, yakumar& Longa Micsel& Gunes, Getey (202) ltematinsoumaot biomaterial 212. 526089, 10.1852012/920058, © 20

  13. Slide 13: Limits of Endogenous Healing

    PolarityTE" Where Seff Regenerates Self” Limits of Endogenous Healing

  14. Slide 14: Goals of Therapy

    Goals of Therapy 22 PolarityTE, Inc. All Rights Reserved. For Investors Only. Not For General Distribution. >) PolarityTE Where Self Regenerates Self Epithelium that prevents bacterial penetration and retains moisture Dermis that is durable yet flexible Dermal appendages that facilitate moisture and

  15. Slide 15: Development of SkinTE

    Where Self Regenerates Sef” Development of SkinTE @ roeviye: Epidermal Cells : = ay = i. , Sebaceous i Follicular Gland Cells = / Bulge Cells Interfollicular Dermis Cells Adipose Derived Cells © 2022 PolarityTE, Inc. All Rights Reserved. For Investors Only. Not For General Distribution.

  16. Slide 16: SkinTE Autologous Heterogeneous Skin Construct (AHSC)

    SkinTE Polarity Autologous Heterogeneous Skin Construct (AHSC) * Where Self Regenerates Self” Multicellular segments with endogenous cellular skin populations including keratinocytes, fibroblasts, endothelial cells, follicular cells, and extracellular matrix Not cultured ex vivo - engrafts and expan

  17. Slide 17: Activation of Wound Healing Pathways

    Activation of Wound Healing Pathways @ rosie Mass Spectrometry Gene Expression Array Gene Expression Array Protein Profiling Stem Cell Pathways Extracellular Matrix Pathways ny A ort oC ¢ ge — ‘Color bey f 2. 4 aM 1 |= | | pa, CS 1 3 ie 33 ‘ 2 | Tn i= oo 4 z _——— {y Native Processed Native Processed

  18. Slide 18: Extensive In Vivo Research and Testing

    Extensive In Vivo Research and Testing PolarityTE” Where Self Regenerates Self Advanced Dressing SkinTE > —— Native ee AS Yucatan Swine (n=8) 36 cm? full-excisional wounds ¢« Arms: Dressing vs SkinTE+Dressing ¢ — SkinTE 1:36 expansion ratio

  19. Slide 19: SkinTE Mechanism of Action

    SkinTE Mechanism of Action @ roeviye * Engraftment of healthy autologous SkinTE multicellular segments * Proliferation and migration of the SkinTE cellular populations * SkinTE expresses growth factors, cytokines, and extracellular matrix supporting the wound bed © 2022 PolarityTE, Inc. All Rights R

  20. Slide 20: SkinTE Testing and Manufacturing Process

    SkinTE is tested to ensure it has the necessary epidermal and dermal cellular components. SI oe Skin Harvest Sent to Manufacturing iratenc SkinTE is tested to ensure cellular i in Self-Cooling Container OLerICY, viability and cellular activation “Harvest size and location may vary SkinTE Returned to

  21. Slide 21: The Goal—Closure with Functional Skin

    The Goal—Closure with Functional Skin PolarityTE” Where Self Regenerates Self Multi-Modality Imaging of Hair Follicles Confocal Confocal ESEM Stereoscopic Merge Dual 2-Point Discrimination Threshold (cm) S a 4 e S$ S = 2 aioe E x a *P < 0.0001 ESEM, environmental scanning electron microscopy; HE, ha

  22. Slide 22: Closure—Not Contracture—From the Inside Out

    Where Self Regenerates Sef” Closure—Not Contracture—From the Inside Out @ roeviye: SkinTE Progression of Healing Over 13 Months’ pd, yh « ie es e — H&E - Highlighting <— Epidermis Rete Pegs’ Punch Biopsy of a region treated with SkinTE — six months following deployment with correlative histology” <—

  23. Slide 23: SkinTE for Diabetic Foot Ulcers

    SkinTE for Diabetic Foot Ulcers @ roeviye: Where Self Regenerates Sef” DFU Outcomes from Pilot Trial? Success in closing DFUs in Initial wound ~9 Meat ateranale Initial wound ~8 weeks after randomized controlled trial and a ee real-world evidence?2:12 SkinTE in Full-Thickness DFUs Oe Pi | Initial wo

  24. Slide 24: SkinTE for Pressure Injury

    SkinTE for Pressure Injury @ roeviye: Where Seff Regenerates Self” Real world evidence supports Residual Limb Pressure Injury22 proof of concept in pressure injury223 Only 50% of stage Ill ulcers and = | 30% of stage IV ulcers heal Initial wound ~11 weeks after single ~23 weeks after single within 6

  25. Slide 25: Published Clinical Data

    Published Clinical Data (sess) RS, ORIGINAL ARTICLE [Reconstructive Openlabel Venous Leg Uleer Pilot Study Using a Novel Autolologous Homologous Skin Construct OD wiry A multicentre, randomised controlled clinical trial evaluating the effects of a novel autologous, heterogeneous skin construct in th

  26. Slide 26: DFU RCT - Statistically Significant Results

    DFU RCT - Statistically Significant Results Application ™ of AHSC £ Number of Applications Primary Endpoint Secondary Endpoint Closure at 12 Weeks Increased Percent Area Reduction Applications of SkinTE (PAR) at 4, 6, 8, 10 and 12 Weeks AHSC: 35/50 (70%) Closed 1 Application: 45/50 (90%) p=0.009 SOC

  27. Slide 27: VLU RCT - Statistically Significant Results

    VLU RCT - Statistically Significant Results Application ™ of AHSC £ Number of Applications Primary Endpoint Secondary Endpoint Closure at 12 Weeks Increased Percent Area Reduction Applications of SkinTE (PAR) at 4, 6, 8, 10 and 12 Weeks AHSC: 10/14 (71%) Closed 1 Application: 13/14 (93%) p=0.000035

  28. Slide 28: Product Portfolio and Pipeline

    Product Portfolio and Pipeline @ rosie Development Status Indication / Application Pre-Regulatory Submission IND Acceptance Trial Enrolling Proof of Concept SkinTE used in over 1,200 clinical cases under the 361 HCT/P Pathway Chronic Cutaneous Wounds: Pivotal Phlll in DFU Diabetic Foot Ulcers, Venou

  29. Slide 29: Pipeline: SkinTE for Acute Trauma

    Pipeline: SkinTE for Acute Trauma Our Opportunity ~84K Trauma cases per year2® This patient cohort is admitted to the hospital with open | sis@d wounds as a primary diagnosis Using tibial type III fractures as a proxy, the wound size ranges from 76-132cm?728 These wounds are highly concentrated in l

  30. Slide 30: Pipeline: SkinTE for Burns

    Pipeline: SkinTE for Burns @ roeviye: Where Self Regenerates Sef” Acute Burn Opportunity Advantageous Positioning SkinTE has demonstrated a ~42K Burn Cases Per year favorable donor site to wound size applicable for SkinTE ratio which is critical in burn?? ~20% of these patients are recording Total B

  31. Slide 31: PolarityTE—Key Takeaways

    PolarityTE—Key Takeaways PolarityTE” Where Sef Regenerates Sof IND Approved & RMAT Des ignation Granted: skinTE IND Accepted for Chronic Cutaneous Ulcers; First Phase 3 Clinical Trial in Wagner 2 DFUs Commenced in Q2 2022; RMAT Designation Granted in Q2 2022 ~1,200 Clinical Cases Focused on Unmet Me

  32. Slide 32: Management Team with Deep Operational, Clinical, and R&D Experience

    Management Team with Deep Operational, Clinical, S PolarityTE™ and Research and Development Experience We ees Management Team Richard Hague Jacob Patterson Nikolai Sopko, MD, PhD Chief Executive Officer & Chief Financial Officer Chief Scientific Officer & | President Vice President R&D } "4 SANOFI G

  33. Slide 33: Board of Directors

    Board of Directors 2022 PolarityTE, Inc. All Rights * Vice Chairman and Lead Director of the Board of Directors of Scientific Games Corporation + Federal Reserve International Capital Markets Advisory Committee David Seaburg Director & Chairman of the Strategic Review Committee + Former Chief Execut

  34. Slide 34: Peer Reviewed Publications

    Peer Reviewed Publications a. “A multicentre, randomised controlled clinical trial evaluating the effects of a novel autologous, heterogeneous skin construct in the treatment of Wagner one diabetic foot ulcers: Interim analysis” in International Wound Journal 2s “Autologous Heterogeneous Skin Constr

  35. Slide 35: References

    Where Self Regenerates Sef” References @ roeviye: = 2022 PolarityTE, Inc. All Rights Reserved. For Investors Onl; Sen, Chandan K. “Human Wounds and Its Burden: An Updated Compendium of Estimates.” Advances in wound care vol. 8,2 (2019): 39-48. doi:10.1089/wound.2019.0946 Armstrong, David G et al. “C

  36. Slide 36: References (Continued)

    Where Self Regenerates Sef” References (Continued) @ roeviye: 18. 19. 20. 21. 22. 23. 24, 25: 26. 27. 28. 29. 30. 31, 32. 33. 34, 2022 PolarityTE, Inc. All Rights Reserved. For Investors Only. Not For General Distri VanGilder C, Macfarlane GD, Meyer S. Results of nine international pressure ulcer pr

  37. Slide 37: Polarity TE”

    Polarity TE” Where Self Regenerates Self” a, me

PolarityTE — Investor Presentation (May 2022) on 6ix